$SNSS Even breast cancer. BTKis and PDK1 inhibitors are really just getting started. You could argue that the PDK1 going after P13K makes that asset just as valuable as Vecabrutinib. Phil had a good term for our pipeline and I have to use it. “boutique molecules”. This is easily acquired. Guaranteed res.mdpi.com/d_attachment/i...
  • 3
3 Likes